AN2 Therapeutics reported net income of -$8.20M for the quarter ended Jun 2026. This income statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.73M | 2.73M | 3.18M | 19.40M | 19.40M | 15.34M | 19.43M | 21.93M | 29.74M | 23.60M | 29.82M | 29.83M | 29.87M | 29.92M | 30.14M | 27.38M | 27.37M | 27.41M | 35.99M | 36.31M | ||
| Operating items | ||||||||||||||||||||||
| Research & DevelopmentR&D | 5.34M | 5.31M | 5.63M | 6.70M | 7.43M | 8.75M | 11.98M | 13.54M | 14.43M | 14.92M | 14.65M | 12.15M | 8.29M | 5.40M | 7.69M | 3.20M | 7.00M | 6.88M | 6.74M | 6.02M | ||
| Selling, General & AdministrativeSG&A | 1.59M | 1.78M | 2.05M | 3.63M | 3.34M | 3.72M | 4.05M | 3.06M | 3.75M | 3.90M | 3.64M | 3.73M | 3.48M | 3.21M | 3.85M | 4.02M | 3.04M | 2.44M | 3.81M | 2.88M | ||
| Restructuring CostsRestructuring | 2.24M | -0.01M | ||||||||||||||||||||
| Other Operating ExpensesOther Opex | 0.50M | 1.00M | ||||||||||||||||||||
| Operating ExpensesOpex | 6.93M | 7.59M | 7.68M | 10.33M | 11.77M | 12.48M | 16.04M | 16.60M | 18.18M | 18.82M | 18.30M | 15.88M | 14.01M | 8.60M | 11.54M | 7.22M | 10.04M | 9.32M | 10.55M | 8.90M | ||
| Operating IncomeOp. Inc | -6.93M | -7.59M | -7.68M | -10.33M | -11.77M | -12.48M | -16.04M | -16.60M | -18.18M | -18.82M | -18.30M | -15.88M | -14.01M | -8.60M | -11.54M | -7.22M | -10.04M | -9.32M | -10.55M | -8.90M | ||
| EBIT | -6.93M | -7.59M | -7.68M | -10.33M | -11.77M | -12.48M | -16.04M | -16.60M | -18.18M | -18.82M | -18.30M | -15.88M | -14.01M | -8.60M | -11.54M | -7.22M | -10.04M | -9.32M | -10.55M | -8.90M | ||
| Non-operating items | ||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.03M | 0.03M | 0.03M | 0.23M | 0.47M | 0.63M | 1.68M | 1.45M | 1.27M | 1.08M | 0.89M | 0.75M | 0.69M | 0.60M | 0.52M | 0.72M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.04M | 0.02M | 0.03M | 0.21M | 0.43M | 0.63M | 0.72M | 0.80M | 1.47M | -2.94M | 0.00M | 1.27M | -0.00M | |||||||||
| Net income details | ||||||||||||||||||||||
| EBT | -6.91M | -7.57M | -7.66M | -10.11M | -11.30M | -11.85M | -16.04M | -16.60M | -18.18M | -18.82M | -16.62M | -14.44M | -12.75M | -7.52M | -10.65M | -6.46M | -9.35M | -8.71M | -10.03M | -8.18M | ||
| Profit After TaxPAT | -6.95M | -7.57M | -7.66M | -10.12M | -11.52M | -11.68M | -15.32M | -15.80M | -16.71M | -16.93M | -16.62M | -14.44M | -12.75M | -7.60M | -10.65M | -6.50M | -9.35M | -8.67M | -10.03M | -8.20M | ||
| Income from Continuing OperationsIncome (Continuing) | -6.91M | -7.57M | -7.66M | -10.11M | -11.30M | -11.85M | -16.04M | -16.60M | -18.18M | -18.82M | -16.62M | -14.44M | -12.75M | -7.52M | -10.65M | -6.46M | -9.35M | -8.71M | -10.03M | -8.18M | ||
| Consolidated Net IncomeConsol Net Inc. | -6.91M | -7.57M | -7.66M | -10.11M | -11.30M | -11.85M | -16.04M | -16.60M | -18.18M | -18.82M | -16.62M | -14.44M | -12.75M | -7.52M | -10.65M | -6.46M | -9.35M | -8.71M | -10.03M | -8.18M | ||
| Income towards Parent CompanyParent Net Inc | -6.91M | -7.57M | -7.66M | -10.11M | -11.30M | -11.85M | -16.04M | -16.60M | -18.18M | -18.82M | -16.62M | -14.44M | -12.75M | -7.52M | -10.65M | -6.46M | -9.35M | -8.71M | -10.03M | -8.18M | ||
| Preferred Dividend PaymentsPref Dividends | 1.93M | 1.93M | 1.82M | |||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -8.87M | -9.47M | -9.47M | -10.12M | -11.34M | -11.84M | -15.32M | -15.80M | -16.71M | -16.90M | -16.62M | -14.44M | -12.75M | -7.52M | -10.65M | -6.46M | -9.35M | -8.71M | -10.03M | -8.19M | ||
| Additional items | ||||||||||||||||||||||
| EPS (Basic) | -3.35 | -3.59 | -2.98 | -0.53 | -0.59 | -0.77 | -0.79 | -0.81 | -0.65 | -0.72 | -0.56 | -0.48 | -0.43 | -0.25 | -0.35 | -0.21 | -0.31 | -0.29 | -0.29 | -0.18 | ||
| EPS (Diluted) | -3.35 | -3.59 | -2.98 | -0.53 | -0.59 | -0.77 | -0.79 | -0.81 | -0.65 | -0.72 | -0.56 | -0.48 | -0.43 | -0.25 | -0.35 | -0.21 | -0.31 | -0.29 | -0.29 | -0.18 | ||
| Shares Outstanding | 2.64M | 2.64M | 3.18M | 19.26M | 19.35M | 15.34M | 19.39M | 19.50M | 25.65M | 23.60M | 29.76M | 29.82M | 29.84M | 29.83M | 30.05M | 30.17M | 30.28M | 30.22M | 34.06M | 44.76M | ||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.64M | 2.64M | 3.18M | 19.26M | 19.35M | 15.34M | 19.39M | 19.50M | 25.65M | 23.60M | 29.76M | 29.82M | 29.84M | 29.83M | 30.05M | 30.17M | 30.28M | 30.22M | 34.06M | 44.76M | ||
| EBITDA | -6.93M | -7.59M | -7.68M | -10.33M | -11.77M | -12.48M | -16.04M | -16.60M | -18.18M | -18.82M | -18.30M | -15.88M | -14.01M | -8.60M | -11.54M | -7.22M | -10.04M | -9.32M | -10.55M | -8.90M |